[REVISION HISTORY]

US generic drug price-fixing settlement

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-10-05 10:20 UTC → 2026-10-09 18:12 UTC · added ~~removed~~

A multistate coalition of 47 45 states and ~~territories, including California, reached a settlement following allegations that several~~ territories is seeking court approval for additional settlements with generic drug manufacturers ~~conspired~~ to ~~fix~~ resolve allegations of a widespread conspiracy to manipulate prices and reduce competition. ~~A U.S. District Court in Connecticut granted preliminary approval~~ Recent developments include agreements with Ascend Laboratories, Mayne Pharma, and Citron Pharma. Ascend and Mayne are expected to pay a ~~settlement plan totaling approximately $96.5~~ combined $1.05 million ~~involving~~ to the states. The settlement with Citron Pharma is non-monetary, as the company has ceased operations. These new agreements include injunctive terms and internal reforms designed to ensure future antitrust compliance. These developments follow previous settlements with companies such as Glenmark, Lannett, Bausch, Apotex, Heritage, Emcure, and Sandoz, which totaled $496.5 million. The coalition is also seeking a $400 million settlement involving Sandoz. Consumers in the United States who purchased eligible generic medications—including treatments for cancer, diabetes, ADHD, and various topical conditions—between May 2009 and December 2019 may be entitled to compensation. To facilitate the process, forty-eight Attorneys General established a composite website for potential claimants to verify information and report claims. While many residents are eligible, specific restrictions apply to residents of Louisiana regarding settlement payments. The deadline for submitting claims is March 8, 2027.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.